Welcome to our dedicated page for BIOXYTRAN news (Ticker: BIXT), a resource for investors and traders seeking the latest updates and insights on BIOXYTRAN stock.
Bioxytran, Inc., an early stage pharmaceutical company, focuses on the development, manufacture, and commercialization of various therapeutic drugs to address hypoxia in humans. The company's lead pharmaceutical drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for the treatment of patients with ischemia of the brain resulting from a stroke or blockage of the blood vessels to the brain. Its products also include BXT-252, an injectable anti-necrosis drug to treat a wound that does not heal because of a limited amount of oxygen reaching the wound. The company was founded in 2017 and is headquartered in Newton, Massachusetts.
Bioxytran, Inc. (OTCQB: BIXT) has reported promising in vitro results for its leading drug candidate ProLectin-M (PL-M), demonstrating a significant reduction in viral load for influenza (H1N1) and Respiratory Syncytial Virus (RSV). Conducted at the Foundation for Neglected Disease Research in India, these tests mirror previous SARS-CoV-2 results that led to successful trials. The company plans to file an IND to advance to phase 2 human clinical trials. With this data, Bioxytran aims to expand treatment options for viral diseases amid the rise of concurrent infections known as the 'tripledemic.'
BIOXYTRAN, INC. (OTCQB: BIXT) has announced that a peer-reviewed article published in Nature Reviews Drug Discovery supports its drug development for fibrosis and antiviral treatments. The article, titled “Targeting galectin-driven regulatory circuits in cancer and fibrosis”, highlights the significance of galectins in diseases like Idiopathic Pulmonary Fibrosis (IPF) and Long COVID. ProLectin-M, an oral drug, showed a 100% responder rate in clinical trials for COVID-19, while ProLectin-I, an intravenous drug, aims to tackle Long COVID and IPF. The ongoing studies and supportive literature enhance the prospects for regulatory approval.
Bioxytran, Inc. (OTCQB: BIXT) announced that CCO Michael Sheikh will participate in a ClearThink IR Virtual Live event on February 15, 2023, at 12 PM ET. The event, hosted via the Paltalk platform, aims to engage potential investors with Q&A discussions about the company’s innovative therapies targeting viral diseases and other medical needs. Bioxytran is focused on developing Prolectin-M, a new class of antiviral drug, along with treatments for pulmonary fibrosis and stroke. Registration for the event is available on their website.
BIOXYTRAN, INC. (OTCQB: BIXT) received Investigational New Drug (IND) authorization from India’s CDSCO to evaluate ProLectin-I for treating Long COVID and Idiopathic Pulmonary Fibrosis (IPF). This IND complements a previous authorization for ProLectin-M. ProLectin-I could address a significant health challenge, with Long COVID affecting 65-100 million globally and an estimated economic cost of $3.7 trillion in the U.S. alone. IPF impacts about 3 million people worldwide. The drug targets viral persistence associated with Long COVID and lung fibrosis.
Bioxytran, Inc. (OTCQB: BIXT) announced that its CMO, Michael Sheikh, will discuss the company's participation in the Emerging Growth Conference on January 25, 2023, at 10:50 am EST. The conference will feature presentations by public companies across various growth sectors, focusing on innovative products and long-term growth potential. Investors are encouraged to preregister for attendance, and an archived webcast will be available post-event. Bioxytran is a clinical-stage biotechnology firm developing therapies for COVID-19 and other diseases, with its lead candidate being Prolectin-M, aimed at treating significant unmet medical needs.
BIOXYTRAN, INC. (OTCQB: BIXT) announced positive outcomes from its Phase 2 clinical trial for ProLectin-M, a treatment for COVID-19. The trial achieved a 100% response rate by day 7 in 34 patients, significantly outperforming the placebo (6%). Additionally, the company received an IND letter from India's CDSCO to optimize dosage for a planned 408 patient Phase III trial. An Indian subsidiary has been established to commercialize ProLectin-M upon approval, utilizing an FDA-approved manufacturing plant aimed at the 1.4 billion population in India.
BIOXYTRAN, INC. (OTCQB: BIXT) announces the establishment of its Indian subsidiary, Pharmalectin India Private Limited, aimed at launching ProLectin-M upon receiving CDSCO approval. The FDA-approved facility is positioned to cater to India's vast market of 1.4 billion. Currently, the company has not secured a distributor for its products. ProLectin-M, Bioxytran's leading drug candidate, targets viral diseases and shows promise in treating unmet medical needs. Further details can be found on their website.
BIOXYTRAN, INC. (OTCQB: BIXT) announced that its CMO, Michael Sheikh, will present the latest clinical trial results at the Emerging Growth Conference on December 14, 2022, from 1:45pm to 2:45pm EST. The conference aims to showcase public companies like Bioxytran, which is developing oral and intravenous therapies for COVID-19 and other viral diseases. Interested investors are encouraged to preregister to attend the conference and access updates. Archived webcasts will also be available for those unable to attend live.
Bioxytran, Inc. (BIXT) has received Investigational New Drug (IND) authorization from India's Central Drugs Standard Control Organization (CDSCO) to optimize dosage in COVID-19 patients. This approval paves the way for a future Phase III trial involving 408 patients, aimed at refining treatment strategies for COVID-19 and other viral diseases. Bioxytran focuses on developing oral and intravenous drugs targeting significant unmet medical needs, particularly with their leading drug candidate, ProLectin-M.
BIOXYTRAN, INC. (OTCQB: BIXT), a clinical stage biotech firm, has announced that Avise Analytics has reinitiated coverage of its stock, setting a fair valuation at $2.71 per share. The report highlights Bioxytran's ProLectin-M, which shows promising recovery rates for Covid-19 patients and targets a multi-billion-dollar market. Additionally, the company is advancing BXT-25 for stroke treatment, addressing the critical treatment window challenge. Despite positive developments, funding limitations could impact drug development timelines. More details can be found in the full report.
FAQ
What is the current stock price of BIOXYTRAN (BIXT)?
What is the market cap of BIOXYTRAN (BIXT)?
What is the focus of Bioxytran, Inc.?
What is the lead pharmaceutical drug candidate of the company?
What is BXT-252?
When was Bioxytran, Inc. founded?
Where is Bioxytran, Inc. headquartered?
What are the contact details for Investor Relations at Bioxytran, Inc.?
What recent achievement has Bioxytran, Inc. made in lesion clearance and regression of Herpes Zoster Neuralgia?
What does the company's patent cover?
What products are included in Bioxytran, Inc.'s portfolio?
What kind of therapeutic drugs does Bioxytran, Inc. manufacture?
